Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2002-12-31

Study Completion Date

2002-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in healthy, non-drug dependent volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5

NCT00000330

Heroin Dependence Opioid-Related Disorders

WITHDRAWN PHASE2

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4

NCT00000329

Heroin Dependence Opioid-Related Disorders

WITHDRAWN PHASE2

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3

NCT00000328

Heroin Dependence Opioid-Related Disorders

WITHDRAWN PHASE2

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1

NCT00000326

Heroin Dependence Opioid-Related Disorders

WITHDRAWN PHASE2

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2

NCT00000327

Heroin Dependence Opioid-Related Disorders

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

not available at this time

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heroin Dependence Opioid-Related Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test Drug

Test drug to prevent heroine withdrawal

Group Type EXPERIMENTAL

Test Drug

Intervention Type DRUG

Placebo Pill

Placebo drug

Group Type PLACEBO_COMPARATOR

Placebo Drug

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Test Drug

Intervention Type DRUG

Placebo Drug

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

test drug o

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Individuals must be healthy, non-drug dependent volunteers, be at least 18 years of age, and have no prior history of drug or alcohol abuse or dependence. Subjects must have had some minimal experience with opioids (e.g. at least two prior exposures)

Exclusion Criteria

Individuals with evidence of an active Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g., liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No